The search for a rapid-acting antidepressant has been a subject of intense research interest for several decades. The article by Lucas and colleagues in this issue of Neuron provides compelling evidence from preclinical animal models that drugs acting at the serotonin 5-HT 4 receptor could finally achieve this goal. However, caution is warranted, as results from animal studies are not always predictive of therapeutic actions in humans.
The search for a rapid-acting antidepressant has been a subject of intense research interest for several decades. The article by Lucas and colleagues in this issue of Neuron provides compelling evidence from preclinical animal models that drugs acting at the serotonin 5-HT 4 receptor could finally achieve this goal. However, caution is warranted, as results from animal studies are not always predictive of therapeutic actions in humans.
A rapid-acting antidepressant has been the holy grail of drug development for mood disorders for many years, as the action of typical antidepressants requires weeks or even months for a beneficial response. Moreover, the efficacy of currently available antidepressants is relatively poor, often requiring patients to try several different agents over the course of many months or even years, and still only about 65% experience a successful treatment response. These are critical issues for the treatment of mood disorders that afflict approximately 17% of the population, resulting in an enormous economic burden, poor quality of life, personal suffering, and suicide.
These concerns highlight the potential significance of the study by Lucas and colleagues (Lucas et al., 2007) demonstrating both rapid and efficacious actions of 5-HT 4 receptor agonists in preclinical, cellular, and behavioral models of depression. If this work translates to the development of rapidacting, clinically effective antidepressant agents, the treatment of these debilitating mood disorders would undergo a sea change. However, clinical trials are needed to test this possibility and to assess potential side effects of these agents.
The selective 5-HT reuptake inhibitors (SSRIs) are the most widely prescribed class of antidepressants. These agents increase synaptic levels of 5-HT relatively quickly (hours or days), but there is a delay in therapeutic response (weeks or months) due to the likely requirement for adaptations at both pre-and postsynaptic sites (Blier and DeMontigny, 1994; Duman et al., 1997; Berton and Nestler, 2006) . At the presynaptic level, desensitization of inhibitory 5-HT 1A autoreceptors must occur to allow for continued firing and release of 5-HT. With typical SSRI antidepressants, this requires several weeks of drug treatment. The first clue that 5-HT 4 receptor agonists might be rapid acting came from earlier studies from this group, demonstrating that these agents increase the firing of 5-HT neurons and that this effect is maximal after only 3 days of agonist exposure (Lucas et al., 2005) . The current study confirms this finding, and the results suggest that the actions of 5-HT 4 agonists include a rapid desensitization of 5-HT 1A autoreceptors (Table 1) . One question is how this rapid occurs. The stimulation of 5-HT neuronal firing (which would lead to higher synaptic levels of 5-HT) could underlie a more rapid desensitization.
At the postsynaptic level, 5-HT 4 receptor agonist administration also leads to a rapid and robust response. Increased postsynaptic receptor function (measured by the activity of 5-HT 1A receptors on CA3 pyramidal cells in the hippocampus) is observed after 3 days of agonist administration compared to several weeks reported for SSRIs, and the magnitude is twice that observed with chronic SSRI treatment (Blier and DeMontigny, 1994; Haddjeri et al., 1998) (Table 1) . These effects are blocked by depletion of 5-HT, further showing the requirement for 5-HT neuronal activation by the 5-HT 4 agonist for an antidepressantlike response. Molecular and cellular markers of antidepressant action were also examined, including phosphorylation of the cAMP response element binding protein (CREB), the active form of this transcription factor, and neurogenesis in the dentate gyrus granule cell layer in the adult hippocampus (Nakagawa et al., 2002; Berton and Nestler, 2006) . Treatment with the 5-HT 4 agonist causes a rapid increase in phospho-CREB, again after only 3 days compared to 2-3 weeks for SSRIs, and a greater response than SSRIs alone (Table 1) (Tiraboschi et al., 2004) . Moreover, agonist treatment rapidly increases neurogenesis in the hippocampus, though this effect is not superior to that observed after SSRI antidepressants. While electroconvulsive seizure rapidly increases hippocampal neurogenesis, this is the first demonstration that a chemical 5-HT agent can also produce such an effect.
Most importantly, the functional significance of these molecular and cellular studies is examined in additional behavioral tests that provide better models for mood disorders and antidepressant actions. While forced swim is a useful, high-throughput, and reliable test, classical antidepressants, including SSRIs, produce a response after 1 or 2 days that is not consistent with the therapeutic time course for these agents (Duman et al., 1997; Berton and Nestler, 2006) . This makes it impossible to determine whether a novel agent has a more rapid onset of action. To address this issue, as well as to examine behaviors with better construct validity, the olfactory bulbectomy and chronic mild stress models were examined. Both of these models require administration of SSRIs for 2-3 weeks before a response is observed, consistent with the therapeutic time course.
In addition, chronic mild stress is considered one of the best animal models that capture core symptoms of depression, including anhedonia, or the inability to experience pleasure (measured by consumption of a sweetened solution) (Berton and Nestler, 2006) . In both of these models, 5-HT 4 receptor agonist administration produces a significant reversal of depressive-like behaviors after 3 days, compared to 2 weeks for an SSRI, providing strong support for the potential rapid actions of these agents (Table 1) .
These exciting findings raise several mechanistic and treatment-related questions. The more rapid response to the 5-HT 4 receptor agonist is most likely a result of parallel rapid and sustained activation of 5-HT neuronal firing, a possibility supported by the electrophysiological studies of both pre-and postsynaptic sites. Increased 5-HT neuronal firing could also underlie the more efficacious effects of 5-HT 4 agonists relative to SSRIs, since the effect of reuptake inhibition is dependent on basal rates of 5-HT cell firing. However, it is also likely that the 5-HT 4 receptor agonists have effects that are independent of 5-HT neuronal firing. This possibility is supported by the ability of these agents to directly activate the cAMP/CREB-regulated signaling pathway (Duman et al., 1997) , while other subtypes inhibit (e.g., 5-HT 1A ) or are not directly coupled to this pathway. Direct actions of 5-HT4 agonists at postsynaptic sites could also underlie the more rapid response to these agents. Additionally, direct application of a 5-HT 4 agonist produces effects on CA3 pyramidal neurons that are opposite to systemic administration of SSRIs or agonists, yet the responses to 5-HT 4 agonists in other hippocampal cell types could differ significantly. This is particularly relevant to the regulation of neurogenesis, which is reported to involve both postsynaptic 5-HT 1A receptors and the cAMP-CREB cascade, and will require further studies to elucidate.
The ability of 5-HT 4 receptors to stimulate 5-HT neuronal firing appears to involve activation of receptors located on neurons in the prefrontal cortex (Lucas et al., 2005) . Although the identity of the cells that express 5-HT 4 receptors and their connections with 5-HT neurons in the dorsal raphe nucleus is not yet known, it is possible that these cells project to other brain regions that could contribute to the antidepressant actions of 5-HT 4 agonists. Another notable aspect of this study is that the actions of 5-HT 4 receptors on neuronal firing and behavior are sustained for several weeks. This is surprising, as most receptors desensitize and/or internalize upon continued activation. The sustained activation and lack of desensitization are most likely related to the partial agonist characteristics of the 5-HT 4 agonist used for these studies (Eglen et al., 1995; Briejer et al., 2001 ), a possibility that requires further analysis and testing. This is a critical point, as sustained activity of future compounds could require similar partial agonist properties.
Although much work remains to be done, the side effects of 5-HT 4 receptor agonists could be fewer or different relative to SSRIs, which would influence the quality of life and treatment compliance of patients taking antidepressant drugs. Most notably, libido is decreased in many SSRI-treated patients, and it is possible that 5-HT 4 agonists may not cause similar effects, although this will require further testing. Expression of 5-HT 4 receptors in the prefrontal cortex and hippocampus is associated with increased learning, memory, and cognition, another potential beneficial effect of 5-HT 4 agonists (Lamirault and Simon, 2001 ). However, 5-HT 4 receptors are also expressed in peripheral tissues, including the gastrointestinal system and heart, and could lead to additional side effects (Hegde and Eglen, 1996) . 5-HT 4 agonists have been used for the treatment of gastrointestinal motility problems, and depending on existing conditions, this could be a benefit or potential problematic side effect. Moreover, 5-HT 4 agonists are associated with atrial arrhythmias, another potential problem that must be closely examined.
In summary, the paper by Lucas and colleagues provides an extensive and convincing data set in support of In two manuscripts published in Neuron (Beg et al. and Wegmeyer et al.) and one published in Cell (Iwasato et al.), investigators have found that a particular GAP, a-chimaerin, is required in vivo for ephrinB3/EphA4-dependent motor circuit formation.
The diversity of signaling molecules has long fascinated scientists and suggested the possibility that particular proteins might be required for specific cellular events. However, examples of signal transduction proteins acting only during particular cellular events have been few and far between. Now, three papers provide a beautiful in vivo example of a specific function for a particular signaling molecule. Together, the three manuscripts are striking for the extent that they each describe a similar set of results but use independent approaches to do so: one group began by identifying a spontaneous mouse mutant (Iwasato et al., 2007) , a second used a yeast two-hybrid screen (Wegmeyer et al., 2007) , and a third used a screen for proteinprotein interactions (Beg et al., 2007).
While each paper offers its own strong evidence for the role of a-chimaerin in mediating ephrinB3/EphA4-dependent motor circuit formation, together these manuscripts provide a compelling and unusually comprehensive picture of an essential role for a particular GAP. Small GTPases in the Rac, Rho, and Cdc42 families act as molecular switches in signaling pathways, with the GTP-bound ''ON'' state and GDPbound ''OFF'' state. Regulating the cycle between ON and OFF are over 70 small RhoGTPase-activating proteins (GAPs) in the mammalian genome, with 12 known to have specific activity for Rac. Chimaerins are RhoGAPs with specific activity for Rac that contain a C1 domain that allows them to bind phorbol esters (Yang and Kazanietz, 2007) . There are two a-chimaerins and two b-chimaerins made as alternatively spliced products of two genes. a2-and b2-chimaerin also contain SH2 domains that enable them to bind phosphorylated tyrosine residues. The a-chimaerin GAPs are expressed in brain and linked to axon guidance (Diaz et al., 2002) , semaphorin signaling (Brown et al., 2004) , dendritic spine development (Buttery et al., 2006) , and the NMDAR ( Van de Ven et al., 2005) . These properties made chimaerin an interesting candidate for regulating axonal growth in the nervous system.
Work from a number of laboratories has identified a specific role of ephrinB3/EphA4 forward signaling in the formation of the motor circuit between neurons in layer 5 of motor cortex and the principle motor neurons in the
